Leerink Partners Maintains BioNTech(BNTX.US) With Buy Rating
Deutsche Bank Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $140
Deutsche Bank Remains a Buy on BioNTech SE (BNTX)
Jefferies Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $149
J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating
BioNTech SE: Promising Clinical Trials and Diversified Oncology Pipeline Support Buy Rating
BioNTech SE (BNTX) Receives a Hold From J.P. Morgan
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), BeiGene (ONC) and BioNTech SE (BNTX)
Jefferies Reaffirms Their Buy Rating on BioNTech SE (BNTX)
Deutsche Bank Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $140
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Opko Health (OPK)
Truist Financial Maintains BioNTech(BNTX.US) With Buy Rating
Truist Financial Sticks to Their Buy Rating for BioNTech SE (BNTX)
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $140
BofA Securities Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $143
Leerink Partners Maintains BioNTech(BNTX.US) With Buy Rating, Raises Target Price to $121
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $140
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Raises Target Price to $140
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $139
H.C. Wainwright Maintains BioNTech(BNTX.US) With Buy Rating, Cuts Target Price to $145